Get it on Google Play

FDA approves rituximab biosimilar for Fresenius Kabi's U.S. portfolio

August 3, 2026 4:09 PM EDT Send to a Friend
Fresenius Kabi, an operating company of Fresenius SE & Co. KGaA (Frankfurt/Xetra: FRE), announced that the U.S. Food and Drug ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login